Generated by AI
Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions. Its lead program, EB-003, is being developed as a next-generation therapeutic candidate, and the broader research platform includes proprietary chemical libraries and additional preclinical assets aimed at mental health indications. Enveric Biosciences works at the intersection of neuroscience, medicinal chemistry, and drug discovery, positioning itself within the evolving field of psychedelic-inspired and neuropsychiatric medicine. The company is headquartered in Cambridge, Massachusetts.
Website245 First Street
Cambridge, MA, 02142
United States
The latest articles about ENVB.
Summary of Jun 4's posts. Generated by AI.
Summary of Apr 28's posts. Generated by AI.
Summary of Apr 27's posts. Generated by AI.
Investors talking about ENVB also mention these. Each card shows that asset’s own numbers for the past 24 hours.